NDA 212306 · Karyopharm Theraps
Xpovio
Selinexor · Oral · Nuclear Export Inhibitor
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Jul 3, 2019
Approved uses
4
Original approval plus efficacy supplements
Registered trials
194
19 Phase 3, 40 recruiting
FAERS reports
8,763
4,819 serious, 1,486 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 12, 2026.
XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody ( 1.1 ). 1.1 Multiple Myeloma XPOVIO in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
Mechanism: In nonclinical studies, selinexor reversibly inhibits nuclear export of tumor suppressor proteins (TSPs), growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1 (XPO1). XPO1 inhibition by selinexor leads to accumulation of TSPs in the nucleus and reductions in several oncoproteins, such as c-myc and cyclin D1, cell cycle arrest, and apoptosis of cancer cells. Selinexor demonstrated pro-apoptotic activity in vitro in multiple myeloma cells and showed anti-tumor activity in murine xenograft models of multiple myeloma. The combination of selinexor and dexamethasone or...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 23, 2026 Supplement 18 · Efficacy LetterLabelMedication Guide
- Dec 18, 2020 Supplement 5 · Efficacy OrphanLabelLetter
- Jun 22, 2020 Supplement 1 · Efficacy · priority review OrphanLabelLetter
- Jul 3, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
6 products under this application
- XPOVIO · SELINEXOR 10MG · TABLET, ORAL · Prescription
- XPOVIO · SELINEXOR 50MG · TABLET, ORAL · Prescription
- XPOVIO · SELINEXOR 20MG · TABLET, ORAL · Prescription
- XPOVIO · SELINEXOR 80MG · TABLET, ORAL · Prescription
- XPOVIO · SELINEXOR 60MG · TABLET, ORAL · Prescription
- XPOVIO · SELINEXOR 40MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Selinexor" as an intervention, any sponsor and status, largest first.
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaPivotal-lookingActive, not recruiting
Karyopharm Therapeutics IncIndustry
NCT04442022 · 501 participants (planned) · Start Sep 3, 2020 · Primary completion Dec 2026
Drug: Selinexor (combination therapy); Selinexor (combination therapy) and 9 more · For: Relapsed/Refractory Diffuse Large B-cell Lymphoma
Sites: Chandler, Arizona; Tucson, Arizona; Cerritos, California · 38 sites in all
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaPivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT06265545 · 458 participants (planned) · Start Feb 22, 2024 · Primary completion Jan 30, 2028
Drug: Ivosidenib; Venetoclax and 7 more · For: AML; Refractory; Relapsed
Sites: Tianjin, China
- COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;Pivotal-lookingCompleted
Peter MacCallum Cancer Centre, AustraliaAcademic, hospital or other
NCT04534725 · 441 participants · Start Dec 17, 2020 · Primary completion Nov 28, 2022
Drug: Interferon alfa; Selinexor and 1 more · For: Cancer; Covid19; Respiratory Viral Infection
Sites: Westmead, Australia; Fitzroy, Australia; Melbourne, Australia · 5 sites in all
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06158841 · 421 participants · Start May 19, 2024 · Primary completion Dec 2027
Drug: Etentamig; Carfilzomib and 5 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Phoenix, Arizona; Berkeley, California · 166 sites in all
- Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaPivotal-lookingCompleted
Karyopharm Therapeutics IncIndustry
NCT03110562 · 402 participants · Start May 24, 2017 · Primary completion Feb 18, 2020
Drug: Selinexor; Bortezomib and 1 more · For: Multiple Myeloma
Sites: Plantation, Florida; Atlanta, Georgia; Honolulu, Hawaii · 157 sites in all
- A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell LymphomaPivotal-lookingRecruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07011056 · 390 participants (planned) · Start Jul 18, 2025 · Primary completion Jun 30, 2029
Drug: Purinostat Mesylate for Injection; Selinexor Tablets · For: Recurrent and Refractory Diffuse Large B-cell Lymphoma
Sites: Chengdu, China
- Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisPivotal-lookingActive, not recruiting
Karyopharm Therapeutics IncIndustry
NCT04562389 · 353 participants · Start Mar 11, 2021 · Primary completion Feb 20, 2026
Drug: Selinexor; Selinexor and 1 more · For: Myelofibrosis
Sites: Birmingham, Alabama; Beverly Hills, California; Duarte, California · 166 sites in all
- Selinexor in Advanced LiposarcomaPivotal-lookingCompleted
Karyopharm Therapeutics IncIndustry
NCT02606461 · 342 participants · Start Jan 4, 2016 · Primary completion Oct 28, 2020
Drug: Selinexor; Placebo · For: Dedifferentiated Liposarcoma
Sites: Los Angeles, California; Santa Monica, California; Stanford, California · 71 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea2,648
- fatigue2,018
- decreased appetite1,406
- diarrhoea1,351
- plasma cell myeloma1,199
- vomiting956
- asthenia880
- death866
- thrombocytopenia768
- platelet count decreased698
- weight decreased654
- off label use545
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 12 |
| 2018 | 14 |
| 2019 | 606 |
| 2020 | 1,378 |
| 2021 | 1,439 |
| 2022 | 1,235 |
| 2023 | 1,222 |
| 2024 | 1,167 |
| 2025 | 1,051 |
| 2026 | 628 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xpovio (Selinexor)
2024 spending
$98.2M
Beneficiaries
1,103
3,428 claims
Per beneficiary
$89,046
$6,013.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $48,683,550 |
| 2021 | $69,551,732 |
| 2022 | $86,816,591 |
| 2023 | $85,562,246 |
| 2024 | $98,217,997 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Vergote I, Pérez-Fidalgo JA, Hamilton EP, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Multicenter Study
- Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S, Simonova M, Spicka I, et al. · Lancet 2020 · Clinical Trial, Phase III, Multicenter Study
- Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial.
Mateos MV, Engelhardt M, Leleu X, et al. · Eur J Haematol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Gasparetto C, Schiller GJ, Tuchman SA, et al. · Br J Cancer 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.
Bose P, Ali H, Al-Ali HK, et al. · J Clin Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A, Vogl DT, Gavriatopoulou M, et al. · N Engl J Med 2019 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Karyopharm Theraps
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.